pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
793
stories
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 24, 26
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
STAT+: European regulators take steps to bolster clinical trial transparency
stat
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
FDA panel confronting peptide controversy
stat
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
fiercebiotech
Jul 23, 26
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
endpoints
Jul 23, 26
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
Jul 23, 26
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
Jul 23, 26
Make or break: Commercial hires critical for success
biospace
Jul 23, 26
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
endpoints
Jul 22, 26
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
Jul 22, 26
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 22, 26
AI data becomes sticking point in biopharma dealmaking
biospace
Jul 21, 26
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
← prev
page 18 of 27
next →
